Insider Cluster (2 insiders) ·Filed Jul 9, 2026

HALO

HALOZYME THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed2mo ago
Insider cluster: 2 insiders, $147K total
Actionable Insight • Neutral

Insider selling is negligible in scale and follows a routine cashless-exercise pattern. No bearish signal for the common stock. Monitor the next 10-Q for fundamentals and pipeline updates, which are the true catalysts for HALO at this valuation.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
HALO ▲ +9.08% at T+20d
NEUTRAL call ✓ call won +9.08% · α vs SPY +6.84% · entry $78.62 → $85.76
Next anchor: T+60d due yesterday
Latest observation: T+57 +21.32% FF3 residual α
Entry anchored
Jul 8, 03:59 PM ET
via exchange tick
T+1d
-3.08%
call -3.08% · α -3.51%
$76.20
settled 3mo ago
T+5d
-1.37%
call -1.37% · α -1.24%
$77.54
settled 3mo ago
T+20d
+9.08%
call +9.08% · α +6.84%
$85.76
settled 8w ago
T+60d
—
call — · α —
—
due yesterday

Price Chart

Loading chart...

Executive Summary

CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substantial cashless-settlement gain. Director Bernadette Connaughton also sold $76K. The $229K total open-market sales represent ~0.002% of HALO's $9.5B market cap — well below any materiality threshold. The CEO's sales are consistent with routine tax-settlement and diversification, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$229.0K
Insiders
2

Key Facts

  • CEO Torley exercised 1,923 derivative shares at $12.07 and simultaneously sold 1,923 shares ($153K total) at ~$80 — a classic cashless exercise pattern
  • Director Connaughton sold 1,000 shares at $76.39 for $76K
  • Total open-market sales of $229K equal ~0.002% of $9.5B market cap
  • Prior 30-day insider activity showed $278K in sales — this cluster is a continuation of routine, small-dollar selling
  • All four insider reports on HALO over the past 4 months have been neutral score 2-3; the stock has averaged +9.4% T+20 across those calls

Financial Impact

Total open-market sales of $229K, representing approximately 0.002% of market capitalization — economically trivial

Risk Factors

  • Insider sales, even small, may be misinterpreted by retail as a negative signal
  • If current selling accelerates beyond $300K/month or involves C-suite without offsetting buys, revisit

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-HALO-1783670523088
6 reports for HALO
Performance horizon
Filters
Rows
Reports for HALO — sortable, filterable
TypeNow
Aug 20, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$106.12 $112.45▲ +5.96%▲ +5.96%$109.25 (+2.94%)
Jul 9, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$78.62 $85.76▲ +9.08%▲ +6.84%$109.25 (+38.95%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$79.45 $83.30▲ +4.85%▲ +5.26%$109.25 (+37.50%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.60 $79.45▲ +10.96%▲ +12.34%$109.25 (+52.58%)
Apr 30, 2026
22w ago
8-K
NEUTRAL ★ 3/10
$63.66 $68.18▲ +7.10%▲ +2.13%$109.25 (+71.61%)
Mar 23, 2026
27w ago
DEFA14A
NEUTRAL ★ 2/10
$62.04 $68.40▲ +10.25%▲ +1.35%$109.25 (+76.09%)
Showing 6 of 6

US Market Status

Market Open — Closes in 3h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 10, 2026